Clinical Trials at Rush Copley
Allergy and Asthma
Blood Disorders and Hematologic Cancers
Breast Cancer
- Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (OFSET)
- Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
- Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer (SCARLET)
Gastrointestinal Cancers
- Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer
- Refractory Small Bowel Adenocarcinoma Treatment Study
- Study for Patients with Hepatocellular Carcinoma (HCC)
- The COMMIT Study: Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
- The DECREASE Study: Treatment of Early-Stage Anal Cancer
Genitourinary Cancers
Head and Neck Cancer
Lung and Chest Tumors
- ALCHEMIST Chemo-IO Study: Treatment for Treatment for Non-Small Cell Lung Cancer
- An ALCHEMIST Treatment Trial: Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer
- Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
- Study of First Line Treatment and Maintenance in Non-Small Cell Lung Cancer
- The ALCHEMIST Screening Trial: Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer